{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:00:52Z","timestamp":1792598452211,"version":"4.5.0"},"reference-count":84,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["brainanddevelopment.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain and Development"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.braindev.2026.104527","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T16:27:39Z","timestamp":1774024059000},"page":"104527","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Emerging disease-modifying therapies for Angelman syndrome: A comprehensive review for pediatric neurologists"],"prefix":"10.1016","volume":"48","author":[{"given":"Debopam","family":"Samanta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.braindev.2026.104527_bb0005","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/GIM.0b013e3181def138","article-title":"Clinical and genetic aspects of Angelman syndrome","volume":"12","author":"Williams","year":"2010","journal-title":"Genet Med"},{"key":"10.1016\/j.braindev.2026.104527_bb0010","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.pediatrneurol.2012.09.015","article-title":"Neurologic manifestations of Angelman syndrome","volume":"48","author":"Thibert","year":"2013","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.braindev.2026.104527_bb0015","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/ajmg.a.36864","article-title":"Angelman syndrome in adulthood","volume":"167a","author":"Larson","year":"2015","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.braindev.2026.104527_bb0020","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2147\/TACG.S57386","article-title":"Angelman syndrome: review of clinical and molecular aspects","volume":"7","author":"Bird","year":"2014","journal-title":"Appl Clin Genet"},{"key":"10.1016\/j.braindev.2026.104527_bb0025","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000328837","article-title":"Molecular and clinical aspects of Angelman syndrome","volume":"2","author":"Dagli","year":"2012","journal-title":"Mol Syndromol"},{"key":"10.1016\/j.braindev.2026.104527_bb0030","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.braindev.2020.08.014","article-title":"Epilepsy in Angelman syndrome: a scoping review","volume":"43","author":"Samanta","year":"2021","journal-title":"Brain Dev"},{"key":"10.1016\/j.braindev.2026.104527_bb0035","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1007\/s10803-020-04861-1","article-title":"Developmental skills of individuals with Angelman syndrome assessed using the Bayley-III","volume":"53","author":"Sadhwani","year":"2023","journal-title":"J Autism Dev Disord"},{"key":"10.1016\/j.braindev.2026.104527_bb0040","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.pedhc.2025.06.005","article-title":"Angelman syndrome: multidisciplinary management","volume":"39","author":"Bridges","year":"2025","journal-title":"J Pediatr Health Care"},{"key":"10.1016\/j.braindev.2026.104527_bb0045","doi-asserted-by":"crossref","first-page":"e1843","DOI":"10.1002\/mgg3.1843","article-title":"A multidisciplinary approach and consensus statement to establish standards of care for Angelman syndrome","volume":"10","author":"Duis","year":"2022","journal-title":"Mol Genet Genomic Med"},{"key":"10.1016\/j.braindev.2026.104527_bb0050","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1080\/13543784.2021.1939674","article-title":"Therapies in preclinical and clinical development for Angelman syndrome","volume":"30","author":"Markati","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.braindev.2026.104527_bb0055","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s13311-021-01082-x","article-title":"Emerging gene and small molecule therapies for the neurodevelopmental disorder Angelman syndrome","volume":"18","author":"Copping","year":"2021","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.braindev.2026.104527_bb0060","doi-asserted-by":"crossref","first-page":"41208","DOI":"10.1074\/jbc.M401302200","article-title":"Biochemical analysis of Angelman syndrome-associated mutations in the E3 ubiquitin ligase E6-associated protein","volume":"279","author":"Cooper","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.braindev.2026.104527_bb0065","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.2217\/epi.15.70","article-title":"Epigenetic regulation of UBE3A and roles in human neurodevelopmental disorders","volume":"7","author":"JM","year":"2015","journal-title":"Epigenomics"},{"key":"10.1016\/j.braindev.2026.104527_bb0070","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s00018-007-6460-0","article-title":"Molecular epigenetics of Angelman syndrome","volume":"64","author":"Lalande","year":"2007","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.braindev.2026.104527_bb0075","author":"FAST"},{"key":"10.1016\/j.braindev.2026.104527_bb0080","doi-asserted-by":"crossref","DOI":"10.1002\/mgg3.734","article-title":"Healthcare burden among individuals with Angelman syndrome: findings from the Angelman syndrome natural history study","volume":"7","author":"Khan","year":"2019","journal-title":"Mol Genet Genomic Med"},{"key":"10.1016\/j.braindev.2026.104527_bb0085","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1111\/j.1528-1167.2009.02108.x","article-title":"Epilepsy in Angelman syndrome: a questionnaire-based assessment of the natural history and current treatment options","volume":"50","author":"Thibert","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.braindev.2026.104527_bb0090","doi-asserted-by":"crossref","DOI":"10.1186\/s11689-023-09494-w","article-title":"Enabling endpoint development for interventional clinical trials in individuals with Angelman syndrome: a prospective, longitudinal, observational clinical study (FREESIAS)","volume":"15","author":"Tjeertes","year":"2023","journal-title":"J Neurodev Disord"},{"key":"10.1016\/j.braindev.2026.104527_bb0095","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/jir.12482","article-title":"Research protocol: the initiation, design and establishment of the global Angelman syndrome registry","volume":"62","author":"Tones","year":"2018","journal-title":"J Intellect Disabil Res"},{"key":"10.1016\/j.braindev.2026.104527_bb0100","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.yebeh.2011.11.027","article-title":"Analysis of EEG patterns and genotypes in patients with Angelman syndrome","volume":"23","author":"Vendrame","year":"2012","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.braindev.2026.104527_bb0105","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1038\/s41380-020-0858-6","article-title":"Angelman syndrome genotypes manifest varying degrees of clinical severity and developmental impairment","volume":"26","author":"Keute","year":"2021","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.braindev.2026.104527_bb0110","doi-asserted-by":"crossref","DOI":"10.1186\/s11689-024-09548-7","article-title":"Developmental milestones and daily living skills in individuals with Angelman syndrome","volume":"16","author":"Sadhwani","year":"2024","journal-title":"J Neurodev Disord"},{"key":"10.1016\/j.braindev.2026.104527_bb0115","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-017-0716-z","article-title":"Unmet clinical needs and burden in Angelman syndrome: a review of the literature","volume":"12","author":"Wheeler","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.braindev.2026.104527_bb0120","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1111\/jir.12635","article-title":"Anxiety-associated and separation distress-associated behaviours in Angelman syndrome","volume":"63","author":"Wheeler","year":"2019","journal-title":"J Intellect Disabil Res"},{"key":"10.1016\/j.braindev.2026.104527_bb0125","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/YPG.0000000000000218","article-title":"Buspirone for the treatment of anxiety-related symptoms in Angelman syndrome: a case series","volume":"29","author":"Balaj","year":"2019","journal-title":"Psychiatr Genet"},{"key":"10.1016\/j.braindev.2026.104527_bb0130","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1177\/0883073808314153","article-title":"Melatonin for chronic insomnia in Angelman syndrome: a randomized placebo-controlled trial","volume":"23","author":"Braam","year":"2008","journal-title":"J Child Neurol"},{"key":"10.1016\/j.braindev.2026.104527_bb0135","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1080\/14656566.2022.2105141","article-title":"Pharmacotherapeutic management of seizures in patients with Angleman syndrome","volume":"23","author":"Samanta","year":"2022","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.braindev.2026.104527_bb0140","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/adc.79.5.423","article-title":"Parental view of epilepsy in Angelman syndrome: a questionnaire study","volume":"79","author":"Ruggieri","year":"1998","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.braindev.2026.104527_bb0145","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1212\/WNL.57.8.1518","article-title":"High-dose ethosuximide for epilepsy in Angelman syndrome: implication of GABA(a) receptor subunit","volume":"57","author":"Sugiura","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.braindev.2026.104527_bb0150","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.yebeh.2018.02.027","article-title":"Diazepam for outpatient treatment of nonconvulsive status epilepticus in pediatric patients with Angelman syndrome","volume":"82","author":"Worden","year":"2018","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.braindev.2026.104527_bb0155","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1001\/archneur.63.1.122","article-title":"Epilepsy in patients with Angelman syndrome caused by deletion of the chromosome 15q11-13","volume":"63","author":"Valente","year":"2006","journal-title":"Arch Neurol"},{"key":"10.1016\/j.braindev.2026.104527_bb0160","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.yebeh.2016.04.030","article-title":"Seizure treatment in Angelman syndrome: a case series from the Angelman syndrome Clinic at Massachusetts General Hospital","volume":"60","author":"Shaaya","year":"2016","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.braindev.2026.104527_bb0165","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.yebeh.2016.12.018","article-title":"Low glycemic index treatment for seizure control in Angelman syndrome: a case series from the Center for Dietary Therapy of epilepsy at the Massachusetts General Hospital","volume":"68","author":"Grocott","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.braindev.2026.104527_bb0170","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-025-04037-z","article-title":"Efficacy and tolerability of a low-glycemic-index ketogenic diet in Angelman syndrome: findings from the DIANE study","volume":"20","author":"Iglesias Escalera","year":"2025","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.braindev.2026.104527_bb0175","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/nature13975","article-title":"Towards a therapy for Angelman syndrome by targeting a long non-coding RNA","volume":"518","author":"Meng","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.braindev.2026.104527_bb0180","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1093\/hmg\/dds130","article-title":"Ube3a-ATS is an atypical RNA polymerase II transcript that represses the paternal expression of Ube3a","volume":"21","author":"Meng","year":"2012","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.braindev.2026.104527_bb0185","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.omtn.2019.12.011","article-title":"Chemical diversity of locked nucleic acid-modified antisense oligonucleotides allows optimization of pharmaceutical properties","volume":"19","author":"Papargyri","year":"2020","journal-title":"Molecular Therapy Nucleic Acids"},{"key":"10.1016\/j.braindev.2026.104527_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102237","article-title":"Strategies to improve the design of gapmer antisense oligonucleotide on allele-specific silencing","volume":"35","author":"Aguti","year":"2024","journal-title":"Molecular Therapy Nucleic Acids"},{"key":"10.1016\/j.braindev.2026.104527_bb0195","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/bdd.2338","article-title":"Biodistribution and delivery of oligonucleotide therapeutics to the central nervous system: advances, challenges, and future perspectives","volume":"44","author":"Goto","year":"2023","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.braindev.2026.104527_bb0200","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abf4077","article-title":"An ASO therapy for Angelman syndrome that targets an evolutionarily conserved region at the start of the UBE3A-AS transcript","volume":"15","author":"Dindot","year":"2023","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.braindev.2026.104527_bb0205","author":"Ciccone"},{"key":"10.1016\/j.braindev.2026.104527_bb0210","series-title":"Ultragenyx announces first patient dosed in Aurora study evaluating GTX-102 in additional Angelman syndrome genotypes and age groups. [internet]","author":"Ultragenyx","year":"2026"},{"key":"10.1016\/j.braindev.2026.104527_bb0215","article-title":"ION582 improves cognition, motor function, and communication in phase 1\/2 trial of Angelman syndrome.[internet]","author":"Meglio","year":"2024","journal-title":"NeurologyLive"},{"key":"10.1016\/j.braindev.2026.104527_bb0220","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1038\/s41591-025-03784-7","article-title":"The UBE3A-ATS antisense oligonucleotide rugonersen in children with Angelman syndrome: a phase 1 trial","volume":"31","author":"Hipp","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.braindev.2026.104527_bb0225","article-title":"Delta rhythmicity is a reliable EEG biomarker in Angelman syndrome: a parallel mouse and human analysis","volume":"9","author":"Sidorov","year":"2017","journal-title":"J Neurodev Disord"},{"key":"10.1016\/j.braindev.2026.104527_bb0230","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.biopsych.2019.01.008","article-title":"Electrophysiological phenotype in Angelman syndrome differs between genotypes","volume":"85","author":"Frohlich","year":"2019","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.braindev.2026.104527_bb0235","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/acn3.51385","article-title":"Delta power robustly predicts cognitive function in Angelman syndrome","volume":"8","author":"Ostrowski","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.braindev.2026.104527_bb0240","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcac106","article-title":"Longitudinal EEG model detects antisense oligonucleotide treatment effect and increased UBE3A in Angelman syndrome","volume":"4","author":"Spencer","year":"2022","journal-title":"Brain Commun"},{"key":"10.1016\/j.braindev.2026.104527_bb0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0027221","article-title":"Adeno-associated virus-mediated rescue of the cognitive defects in a mouse model for Angelman syndrome","volume":"6","author":"Daily","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.braindev.2026.104527_bb0250","unstructured":"Stansfield N. MavriX Bio\u2019s Angelman Syndrome Gene Therapy MVX-220 Garners FDA Fast Track Designation.[Internet] CGTLive. September 28, 2025. Updated October 3, 2025. Accessed February 26, 2026. https:\/\/www.cgtlive.com\/view\/mavrix-bio-angelman-syndrome-gene-therapy-mvx-220-garners-fda-fast-track-designation."},{"key":"10.1016\/j.braindev.2026.104527_bb0255","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1007\/s13311-022-01239-2","article-title":"Improving gene therapy for Angelman syndrome with secreted human UBE3A","volume":"19","author":"Nenninger","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.braindev.2026.104527_bb0260","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.144712","article-title":"Dual-isoform hUBE3A gene transfer improves behavioral and seizure outcomes in Angelman syndrome model mice","volume":"6","author":"Judson","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.braindev.2026.104527_bb0265","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/hmg\/ddab104","article-title":"Functional rescue in an Angelman syndrome model following treatment with lentivector transduced hematopoietic stem cells","volume":"30","author":"Adhikari","year":"2021","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.braindev.2026.104527_bb0270","doi-asserted-by":"crossref","DOI":"10.1172\/JCI142574","article-title":"CRISPR\/Cas9 directed to the Ube3a antisense transcript improves Angelman syndrome phenotype in mice","volume":"131","author":"Schmid","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.braindev.2026.104527_bb0275","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41586-020-2835-2","article-title":"Cas9 gene therapy for Angelman syndrome traps Ube3a-ATS long non-coding RNA","volume":"587","author":"Wolter","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.braindev.2026.104527_bb0280","doi-asserted-by":"crossref","DOI":"10.1038\/s42003-025-08794-2","article-title":"AAV-dCas9 vector unsilences paternal Ube3a in neurons by impeding Ube3a-ATS transcription","volume":"8","author":"Wolter","year":"2025","journal-title":"Commun Biol"},{"key":"10.1016\/j.braindev.2026.104527_bb0285","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1016\/j.ymthe.2023.02.015","article-title":"A high-fidelity RNA-targeting Cas13 restores paternal Ube3a expression and improves motor functions in Angelman syndrome mice","volume":"31","author":"Li","year":"2023","journal-title":"Mol Ther"},{"key":"10.1016\/j.braindev.2026.104527_bb0290","article-title":"Brain-wide genome editing via STEP-RNPs for treatment of Angelman syndrome","author":"Lu","year":"2025","journal-title":"bioRxiv"},{"issue":"1","key":"10.1016\/j.braindev.2026.104527_bb0295","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41434-025-00582-1","article-title":"Multi-targeting zinc finger nuclease vector unsilences paternal UBE3A in a mouse model of Angelman syndrome","volume":"33","author":"Bazick","year":"2026","journal-title":"Gene Ther"},{"key":"10.1016\/j.braindev.2026.104527_bb0300","author":"FAST"},{"key":"10.1016\/j.braindev.2026.104527_bb0305","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/mt.2015.236","article-title":"Protein delivery of an artificial transcription factor restores widespread Ube3a expression in an Angelman syndrome mouse brain","volume":"24","author":"Bailus","year":"2016","journal-title":"Mol Ther"},{"key":"10.1016\/j.braindev.2026.104527_bb0310","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.ymthe.2023.01.013","article-title":"Transcriptional reprogramming restores UBE3A brain-wide and rescues behavioral phenotypes in an Angelman syndrome mouse model","volume":"31","author":"O\u2019Geen","year":"2023","journal-title":"Mol Ther"},{"key":"10.1016\/j.braindev.2026.104527_bb0315","author":"FAST"},{"key":"10.1016\/j.braindev.2026.104527_bb0320","first-page":"1","article-title":"CRISPR activation for SCN2A-related neurodevelopmental disorders","author":"Tamura","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.braindev.2026.104527_bb0325","author":"FAST"},{"key":"10.1016\/j.braindev.2026.104527_bb0330","doi-asserted-by":"crossref","DOI":"10.1038\/s41421-024-00727-3","article-title":"Epigenetic editing alleviates Angelman syndrome phenotype in mice by unsilencing paternal Ube3a","volume":"10","author":"Liu","year":"2024","journal-title":"Cell Discov"},{"key":"10.1016\/j.braindev.2026.104527_bb0335","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nature10726","article-title":"Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons","volume":"481","author":"Huang","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.braindev.2026.104527_bb0340","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.nbd.2017.05.010","article-title":"Rescue of altered HDAC activity recovers behavioural abnormalities in a mouse model of Angelman syndrome","volume":"105","author":"Jamal","year":"2017","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.braindev.2026.104527_bb0345","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-49788-8","article-title":"Ube3a unsilencer for the potential treatment of Angelman syndrome","volume":"15","author":"Vihma","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.braindev.2026.104527_bb0350","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3004655","article-title":"Decreased tonic inhibition in cerebellar granule cells causes motor dysfunction in a mouse model of Angelman syndrome","volume":"4","author":"Egawa","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.braindev.2026.104527_bb0355","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/aur.2418","article-title":"CIM6P\/IGF-2 receptor ligands reverse deficits in Angelman syndrome model mice","volume":"14","author":"Cruz","year":"2021","journal-title":"Autism Res"},{"key":"10.1016\/j.braindev.2026.104527_bb0360","doi-asserted-by":"crossref","first-page":"12500","DOI":"10.1073\/pnas.1820131116","article-title":"UBE3A-mediated PTPA ubiquitination and degradation regulate PP2A activity and dendritic spine morphology","volume":"116","author":"Wang","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.braindev.2026.104527_bb0365","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.neuropharm.2018.10.038","article-title":"Enhancement of synaptic plasticity and reversal of impairments in motor and cognitive functions in a mouse model of Angelman syndrome by a small neurogenic molecule, NSI-189","volume":"144","author":"Liu","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.braindev.2026.104527_bb0370","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.nbd.2016.08.002","article-title":"Ketone ester supplementation attenuates seizure activity, and improves behavior and hippocampal synaptic plasticity in an Angelman syndrome mouse model","volume":"96","author":"Ciarlone","year":"2016","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.braindev.2026.104527_bb0375","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-019-3996-x","article-title":"Evaluation of the safety and tolerability of a nutritional formulation in patients with ANgelman syndrome (FANS): study protocol for a randomized controlled trial","volume":"21","author":"Herber","year":"2020","journal-title":"Trials"},{"key":"10.1016\/j.braindev.2026.104527_bb0380","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1111\/jir.70026","article-title":"Criterion validity, scalability and stability of scoring on the Bayley-III in children with Angelman syndrome","volume":"69","author":"Ten Hooven-Radstaake","year":"2025","journal-title":"J Intellect Disabil Res"},{"key":"10.1016\/j.braindev.2026.104527_bb0385","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-025-03817-x","article-title":"Using the Bayley-4 and Vineland-3 in Angelman syndrome: barriers, solutions, and challenging items","volume":"20","author":"Halpin","year":"2025","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.braindev.2026.104527_bb0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2025.11.021","article-title":"Developing meaningful score differences for the Bayley-4 and Vineland-3 in Angelman syndrome using a Delphi panel","author":"Powers","year":"2026","journal-title":"Value Health"},{"key":"10.1016\/j.braindev.2026.104527_bb0395","doi-asserted-by":"crossref","DOI":"10.1186\/s11689-025-09655-z","article-title":"Development of the Angelman syndrome video assessment: quantifying meaningful change","volume":"17","author":"Sheehy","year":"2025","journal-title":"J Neurodev Disord"},{"issue":"1","key":"10.1016\/j.braindev.2026.104527_bb0400","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s41687-025-00975-1","article-title":"Advancing observer-reported outcome measurement: development of the MOOD-AS for observing distress in Angelman syndrome","volume":"10","author":"Halpin","year":"2025","journal-title":"J Patient Rep Outcomes"},{"key":"10.1016\/j.braindev.2026.104527_bb0405","doi-asserted-by":"crossref","DOI":"10.1186\/s11689-020-09349-8","article-title":"Development of an adapted clinical global impression scale for use in Angelman syndrome","volume":"13","author":"Kolevzon","year":"2021","journal-title":"J Neurodev Disord"},{"key":"10.1016\/j.braindev.2026.104527_bb0410","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ejpn.2023.08.003","article-title":"An adapted clinical global impression of improvement for use in Angelman syndrome: validation analyses utilizing data from the NEPTUNE study","volume":"47","author":"Ventola","year":"2023","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.braindev.2026.104527_bb0415","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1352\/1944-7558-128.3.204","article-title":"Validation of the observer-reported communication ability (ORCA) measure for individuals with Angelman syndrome","volume":"128","author":"Zigler","year":"2023","journal-title":"Am J Intellect Dev Disabil"},{"key":"10.1016\/j.braindev.2026.104527_bb0420","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.41911","article-title":"Feasibility of screening for chromosome 15 imprinting disorders in 16 579 newborns by using a novel genomic workflow","volume":"5","author":"Godler","year":"2022","journal-title":"JAMA Netw Open"}],"container-title":["Brain and Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760426000288?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760426000288?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T06:48:39Z","timestamp":1780296519000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0387760426000288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":84,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0387760426000288"],"URL":"https:\/\/doi.org\/10.1016\/j.braindev.2026.104527","relation":{},"ISSN":["0387-7604"],"issn-type":[{"value":"0387-7604","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging disease-modifying therapies for Angelman syndrome: A comprehensive review for pediatric neurologists","name":"articletitle","label":"Article Title"},{"value":"Brain and Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.braindev.2026.104527","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Japanese Society of Child Neurology. Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104527"}}